Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 12Gastrointestinal 5NET 3Genitourinary 3Dermatologic 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Neoplasms 1Meningioma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × pasireotide × CNS × Clear all
NCT00813592 2014-06-11

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

University of Utah

Phase 2 Terminated
2 enrolled 6 charts
CNS

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡